14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score -3.044 5 days ( 0 % )
Last Price $2.22 -1.77 %
High/ Low $2.22 - $2.29 -1.80%
Chg 7 Days -5.13 % $2.34 $2.22
Chg 30 Days -21.28 % $2.82 $2.22
Chg 12 mos 63.24 % $1.36 $2.22
Trend - 3 mos 97.80 % Width: 52.13 %
Trend - 12 mos 31.11 % Width: 122.12 %
Pred. range - 3 mos $4.37 - $6.65 96.95 % - 199.61 %
Pred. range - 12 mos $1.73 - $3.84 -22.09 % - 73.05 %
Short MA avg 3 mos Sell Apr 15, 2024 - 8 days
Long MA avg 3 mos Sell Apr 17, 2024 - 6 days
Short/Long MA avg 3 mos Sell Apr 22, 2024 - 3 days
Short MA avg 12 mos Sell Apr 15, 2024 - 8 days
Long MA avg 12 mos Sell Feb 05, 2024 - 56 days
Short/Long MA avg 12 mos Buy Feb 13, 2024 - 50 days
Pivot Short Sell Mar 28, 2024 - 19 days
Bollinger Buy Mar 12, 2024 - 31 days
MACD Sell No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About Regulus Therapeutics Inc.

Regulus Therapeutics. Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study... RGLS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT